会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Treatment of tropical spastic paresis with peptide T
    • 用T肽治疗热带痉挛性麻痹
    • US06242564B1
    • 2001-06-05
    • US07898691
    • 1992-06-15
    • Candace B. PertMichael R. Ruff
    • Candace B. PertMichael R. Ruff
    • A61K3702
    • C07K14/005A61K38/162A61K39/00C07K14/70514C07K16/1063C12N2740/16122
    • Intranasal therapy using short peptides of the formula (I): Ra-Ser-Thr-Thr-Thr-Asn-Tyr-Rb  (I) where Ra represents an amino terminal residue Ala-, D-Ala or Cys-Ala- and Rb represents a carboxy terminal residue -Thr, -Thr-amide, -Thr-Cys or -Thr-Cys-amide, or a derivative thereof, or a peptide of formula (II): R1-R2-R3-R4-R5  (II) where R1 is an amino terminal residue XR6 or R6 wherein R6 is Thr-, Ser-, Asn-, Leu-, Ile-, Arg- or Glu- and X is Cys, R2 is Thr, Ser or Asp, R3 is Thr, Ser, Asn, Arg, Gln, Lys or Trp, R4 is Tyr and R5 is a carboxy terminal residue which is R7X or R7 wherein R7 may be any amino acid and X is Cys, or an ester or amide derivative thereof, or a physiologically acceptable salt of (I) or (II) is disclosed. Such peptides bind to T4 receptors and are useful for intranasal administration in preventing viral infectivity in mammals by viruses which bind to the T4 receptors. These peptides are believed to act as competitive blocking agents.
    • 使用式(I)的短肽的鼻内治疗:其中Ra表示氨基末端残基Ala-,D-Ala或Cys-Ala-和Rb表示羧基末端残基-Thr,-Thr-amide,-Thr-Cys或 -Thr-Cys-酰胺或其衍生物或式(II)的肽:其中R 1是氨基末端残基XR 6或R 6,其中R 6是Thr-,Ser-,Asn-,Leu-,Ile-,Arg- 或Glu-和X是Cys,R2是Thr,Ser或Asp,R3是Thr,Ser,Asn,Arg,Gln,Lys或Trp,R4是Tyr,R5是R7X或R7的羧基末端残基,其中R7可以是 任何氨基酸和X是Cys,或其酯或酰胺衍生物,或(I)或(II)的生理学上可接受的盐。 这些肽与T4受体结合,并且可用于通过结合T4受体的病毒预防哺乳动物的病毒感染性进行鼻内给药。 据信这些肽作为竞争性阻断剂。
    • 6. 发明授权
    • Small peptides which inhibit binding to T-4 receptors and act as
immunogens
    • 抑制与T-4受体结合并作为免疫原的小肽
    • US5276016A
    • 1994-01-04
    • US568616
    • 1990-08-16
    • Candace B. PertMichael R. RuffWilliam L. Farrar
    • Candace B. PertMichael R. RuffWilliam L. Farrar
    • A61K38/00A61K39/00C07K14/16C07K14/73C07K16/10A61K37/02C07K7/06
    • C07K14/005C07K14/70514C07K16/1063A61K38/00A61K39/00C12N2740/16122Y10S514/885
    • Short peptide of the formula:R.sup.a -Ser-Thr-Thr-Thr-Asn-Tyr-R.sup.b (I)where R.sup.a represents an amino terminal residue Ala- or D-Ala and R.sup.b represents a carboxy terminal residue -Thr or -Thr amide or a derivative thereof with an additional Cys- residue at one or both of the amino and carboxy terminals, or a peptide of formula (II):R.sup.1 -R.sup.2 -R.sup.3 -R.sup.4 -R.sup.5 (II)whereR.sup.1 is an amino terminal residue Thr-, Ser-, Asn-,Leu-,Ile-,Arg- or Glu-R.sup.2 is Thr, Ser or AspR.sup.3 is Thr, Ser, Asn, Arg, Gln, Lys or TrpR.sup.4 is Tyr andR.sup.5 is a carboxy terminal amino group or a derivative thereof with a corresponding D- amino acid as the amino terminal residue, and/or a corresponding amide derivative at the carboxy terminal residue and/or additionally a Cys- residue at one or both of the amino and carboxy terminals,or a physiologically acceptable salt thereof.Such peptides bind to T4 receptors are useful in preventing viral infectivity by viruses which bind to the T4 receptors. These peptides are believed to act as competitive blocking agents.
    • 下式的短肽:Ra-Ser-Thr-Thr-Thr-Asn-Tyr-Rb(I)其中Ra表示氨基末端残基Ala-或D-Ala,Rb表示羧基末端残基-Thr或-Thr酰胺 或其衍生物在氨基和羧基末端的一个或两个上具有另外的Cys-残基,或式(II)的肽:R 1 -R 2 -R 3 -R 4 -R 5(II)其中R 1是氨基末端残基Thr - ,Ser-,Asn-,Leu-,Ile-,Arg-或Glu-R2是Thr,Ser或Asp R3是Thr,Ser,Asn,Arg,Gln,Lys或Trp R4是Tyr,R5是羧基末端 氨基或其衍生物与相应的D-氨基酸作为氨基末端残基,和/或羧基末端残基处的相应酰胺衍生物和/或另外在氨基和羧基末端的一个或两个上的Cys-残基, 或其生理上可接受的盐。 与T4受体结合的这些肽可用于通过结合T4受体的病毒来预防病毒感染性。 据信这些肽作为竞争性阻断剂。